Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.

Published in:

Breast Cancer Research & Treatment, 2020, v. 181, n. 1, p. 97, doi. 10.1007/s10549-020-05604-7

By:

• Denys, Hannelore;
• Martinez-Mena, Corina L.;
• Martens, Marc T.;
• D'Hondt, Randal G.;
• Graas, Marie-Pascale L.;
• Evron, Ella;
• Fried, Georgeta;
• Ben-Baruch, Noa E.;
• Vulsteke, Christof;
• Van Steenberghe, Mona M.

Publication type:

Article